NCT Number: NCT02784314
Cost Efficacy Evaluation of Robot Assisted Radical Prostatectomy
In this observational cost efficacy study, the investigator compare the Laparoscopic Radical Prostatectomy (LRP) versus Robotic-Assisted Laparoscopic Prostatectomy (RALP). Every cost of care that include hospitalization related or post operative medical consumption are obtained and recorded up to 5 years follow up. Functional results (continence, potency, quality of life) are obtained through standardised questionnaires. Carcinologic results are estimated by Prostate Specific Antigen (PSA) relapse and salvage treatments. Economic evaluation will be made to estimate direct costs of the four postoperative year along with the incremental cost-effectiveness ratio (ICER) per successful surgical treatment (preserved urinary continence and erectile function and PSA < 0.2).
Looking for future studies?
Notify MeKey information
Conditions
Age range
40 year–70 year
Sex eligibility
Male
Study type
Interventional
Phase
Not applicable
Primary location
Service d'Urologie - Clinique St Augustin, Bordeaux, France
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Localized prostate cancer
- Gleason grade ≤ 3 + 4
- PSA < 15 ng / mL
- Stage ≤ T2b
- Eligible to receive laparoscopic radical prostatectomy
- Candidate bilateral or unilateral erectile preservation
Exclusion criteria
- Patient at high risk of postoperative progression (PSA> 15 ng / mL; grade 5 predominant, clinical or radiological stage T3
- Presenting erectile dysfunction (IIEF < 22)
- Past history of urinary incontinence (> grade 1 WHO)
- Body mass index > 30
Treatment and study plan
Laparoscopic Radical Prostatectomy
ProcedurePrimary outcomes
-
Erectile function
Time frame: 12 months after surgery
Proportion of patients with recovery of erectile function between T0 (before surgery) and 12 months after surgery. Recovery is defined as a maximum decrease of 5 points score of the International Index of Erectile Function (IIEF) between pre and postoperative evaluations.
Secondary outcomes
-
Surgical margins
Time frame: During surgery
-
Prostate Specific Antigen (PSA)
Time frame: Before surgery (T0), 6 months (M6), 12 months (M12), 24 months (M24) and 60 months (M60) after surgery
-
Continence
Time frame: Before surgery (T0), 6 months (M6), 9 months (M9),12 months (M12), 24 months (M24) and 60 months (M60) after surgery
Continence is assessed by the International Prostate Symptom Score (IPSS)
-
Tolerance
Time frame: Perioperative period, 6 months (M6), 12 months (M12) and 24 months (M24) afer surgery
Adverse events related to the perioperative prostatectomy, 6 months, 12 months and 24 months afer surgery
-
Quality of life
Time frame: Before surgery (T0), 6 months (M6), 9 months (M9),12 months (M12) and 24 months (M24) after surgery
Quality of life is assessed by EQ-5D, QLQ-C30 and QLQ-PR25 scores
-
Incremental cost-effectiveness ratio
Time frame: 60 months afet surgery
Economic evaluation will be made to estimate direct costs of the five postoperative years along with the incremental cost-effectiveness ratio (ICER) per successful surgical treatment
Sponsors and collaborators
Lead sponsor
Hospices Civils de Lyon
Other
Registry information
Official study title
Medico-economic Evaluation of Robotic-assisted Radical Prostatectomy Versus Laparoscopic Radical Prostatectomy
Acronym: ROBOTCAP
Important dates
- Study start
- 2010
- Primary completion
- 2013
- Study completion
- 2016
- First posted
- May 27, 2016
- Registry last updated
- Jun 5, 2017
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Virtual Reality Headset and/or Aromatherapy for Patients Undergoing a Transperineal Prostate Biopsy
NCT06296147
Genital Diseases, Genital Diseases, Male
Pittsburgh, Pennsylvania, United States
View Trial DetailsA Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer
NCT06395753
Genital Diseases, Genital Diseases, Male
Mesa, Arizona, United States
View Trial DetailsEvaluation of Targeted Prostate Biopsies Under MRI: Tolerance and Contribution in the Therapeutic Decision - Exploratory Study
NCT05612204
Genital Diseases, Genital Diseases, Male
Antony, France
View Trial DetailsMichigan Genetic Hereditary Testing (MiGHT)
NCT05162846
Adnexal Diseases, Breast Cancer
Ann Arbor, Michigan, United States
View Trial Details